Bin Zhu
VP, BD GeneScience Pharm.
Bin Zhu is the Vice President of International Business Development at Changchun GeneScience Pharmaceuticals and has 7 Years of Business Development Experience with Simcere and Qilu Pharmaceutical Groups in USA and China. 20 Years of Drug Discovery and Development Experience with Eisai, UK, Sanofi USA, Takeda Singapore, GSK Singapore and Wuxi-AppTec China.
Seminars
Thursday 3rd December 2026
The Investor Lens on Amylin: Where Will Capital Flow in the Next Wave of Obesity Innovation?
12:00 pm
- Assess what is driving investor conviction in amylin, from major pharma prioritisation and billion-dollar partnering activity to growing interest in preclinical assets, and determine whether the field represents the next major investment cycle after GLP-1s
- Define what makes an amylin company or asset investable, examining which differentiators – efficacy, tolerability, receptor profile, oral or long-acting delivery, combination potential and quality of weight loss – are most likely to justify financing and strategic interest as the competitive landscape expands
- Explore how investors should balance opportunity against scientific risk, identifying the clinical and translational milestones needed to de-risk programmes, where there is still whitespace for new entrants, and when partnering, acquisition or continued independent development creates the greatest value
